Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women

Summary

The tumor necrosis factor (TNF) pathway may be implicated in etiopathogenesis of PAI-1 overexpression during obesity. The aim of this study was to investigate the influence of polymorphismA36G of the TNF receptor 1 (TNFRSF1A +36A/G) on plasma concentrations of PAI-1 in 163 obese (31 with the metabolic syndrome, MetS) and 150 lean, healthy women. Genotypic and allele frequencies did not significantly differ between obese and lean subjects. TNFRSF1A genotypes were significantly associated with sTNFR1 plasma levels in obese women only (p<0.01); TNFRSF1A +36G/G obese carriers exhibited higher sTNFR1 and PAI-1 levels than A carriers (p<0.01 and p<0.05, respectively). In obese women, the presence of the MetS significantly potentiated the elevation of sTNFR1 and PAI-1 levels observed in the TNFRSF1A+36G/G carriers. Our results suggest that association between TNFRSF1A +36G/G genotype and the MetS renders obese women more prone to activation of the TNF pathway reflected by high circulating sTNFR1 and PAI-1 levels.

Keywords

Obesity - metabolic syndrome - inflammation - TNFR1 - PAI-1

• References

• 1 Festa A, D'Agostino Jr. R, Tracy RP. et al Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
• 2 Festa A, Williams K, Tracy RP. et al Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 1753-9.
• 3 Kanaya AM, Wassel Fyr C, Vittinghoff E. et al Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 2006; 166: 350-6.
• 4 Hoffstedt J, Andersson IL, Persson L. et al The common –675 4G/5G polymorphism in the plasminogen activator inhibitor –1 gene is strongly associated with obesity. Diabetologia 2002; 45: 584-7.
• 5 Lopes C, Dina C, Durand E. et al PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia 2003; 46: 1284-90.
• 6 Bouchard L, Mauriege P, Vohl MC. et al Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Quebec Family Study: evidence of interactions with menopause. Menopause 2005; 12: 136-43.
• 7 Nam TJ, Busby Jr. W, Clemmons DR. Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. Endocrinology 1997; 138: 2972-8.
• 8 Lebrun P, Baron V, Hauck CR. et al Cell adhesion and focal adhesion kinase regulate insulin receptor substrate-1 expression. J Biol Chem 2000; 275: 38371-7.
• 9 Lopez-Alemany R, Redondo JM, Nagamine Y. et al Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 2003; 270: 814-21.
• 10 Liang X, Kanjanabuch T, Mao SL. et al Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 2006; 290: E103-E113.
• 11 Schafer K, Fujisawa K, Konstantinides S. et al Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic pro-file of genetically obese and diabetic ob/ob mice. Faseb J 2001; 15: 1840-2.
• 12 Lijnen HR, Maquoi E, Morange P. et al Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2003; 23: 78-84.
• 13 Ma LJ, Mao SL, Taylor KL. et al Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53: 336-46.
• 14 Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999; 245: 621-5.
• 15 Chu NF, Chang JB, Shieh SM. Plasma leptin, fatty acids, and tumor necrosis factor-receptor and insulin resistance in children. Obes Res 2003; 11: 532-40.
• 16 Dzienis-Straczkowska S, Straczkowski M, Szelachowska M. et al Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care 2003; 26: 875-80.
• 17 You T, Ryan AS, Nicklas BJ. The metabolic syndrome in obese postmenopausal women: relationship to body composition, visceral fat, and inflammation. J Clin Endocrinol Metab 2004; 89: 5517-22.
• 18 Grunnet L, Poulsen P, Klarlund Pedersen B. et al Plasma cytokine levels in young and elderly twins: genes versus environment and relation to in vivo insulin action. Diabetologia 2006; 49: 343-50.
• 19 Samad F, Uysal KT, Wiesbrock SM. et al Tumor necrosis factor alpha is a key component in the obesitylinked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999; 96: 6902-7.
• 20 Bastelica D, Mavri A, Verdierl M. et al Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNFalpha receptors to PAI-1 levels. Thromb Haemost 2002; 88: 481-7.
• 21 Dieude P, Osorio J, Petit-Teixeira E. et al A TNFR1 genotype with a protective role in familial rheumatoid arthritis. Arthritis Rheum 2004; 50: 413-9.
• 22 Matthews DR, Hosker JP, Rudenski AS. et al Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
• 23 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
• 24 Schreyer SA, Chua Jr. SC, LeBoeuf RC. Obesity and diabetes in TNF-alpha receptor-deficient mice. J Clin Invest 1998; 102: 402-11.
• 25 Conraads VM, Bosmans JM, Schuerwegh AJ. et al Association of lipoproteins with cytokines and cytokine receptors in heart failure patients. Differences between ischaemic versus idiopathic cardiomyopathy. Eur Heart J 2003; 24: 2221-6.
• 26 Popa C, Netea MG, Radstake T. et al Influence of anti-TNF treatment on the cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-5.
• 27 Tsukui S, Kanda T, Nara M. et al Moderate-intensity regular exercise decreases serum tumor necrosis factor-alpha and HbA1c levels in healthy women. Int J Obes Relat Metab Disord 2000; 24: 1207-11.
• 28 Memon RA, Grunfeld C, Moser AH. et al Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993; 132: 2246-53.
• 29 Khovidhunkit W, Kim MS, Memon RA. et al Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-96.
• 30 Morange PE, Saut N, Alessi MC. et al Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis 2005; 179: 317-23.
• 31 Aksentijevich I, Galon J, Soares M. et al The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69: 301-14.
• 32 Poirier O, Nicaud V, Gariepy J. et al Polymorphism R92Q of the tumour necrosis factor receptor 1 gene is associated with myocardial infarction and carotid intima-media thickness--the ECTIM, AXA, EVA and GENIC Studies. Eur J Hum Genet 2004; 12: 213-9.